Tulosta

Fibraatit

Lisätietoa aiheesta
5.3.2013
Antero Kesäniemi

Kirjallisuutta

  1. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978;40:1069-118 «PMID: 361054»PubMed
  2. Frick MH, Elo O, Haapa K ym. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45 «PMID: 3313041»PubMed
  3. Rubins HB, Robins SJ, Collins D ym. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8 «PMID: 10438259»PubMed
  4. Manninen V, Tenkanen L, Koskinen P ym. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45 «PMID: 1728471»PubMed
  5. Bloomfield Rubins H, Davenport J, Babikian V ym. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33 «PMID: 11401940»PubMed
  6. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7 «PMID: 10880410»PubMed
  7. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10 «PMID: 11289345»PubMed
  8. Keech A, Simes RJ, Barter P ym. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61 «PMID: 16310551»PubMed
  9. Gould AL, Rossouw JE, Santanello NC ym. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946-52 «PMID: 9529261»PubMed
  10. Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-5 «PMID: 11705478»PubMed
  11. Palva E. Statiinit, myalgia ja rabdomyolyysi Suomessa. Tabu 2001;9:19
  12. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998;19:355-71 «PMID: 9825949»PubMed
  13. Bloomfield Rubins H, Davenport J, Babikian V ym. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33 «PMID: 11401940»PubMed
Käypä hoito -suositukset ovat riippumattomia, tutkimusnäyttöön perustuvia kansallisia hoitosuosituksia. Lue lisää
KÄYPÄ HOITO -SUOSITUS Dyslipidemiat
LINKKIEN TYYPIT JA VÄRIKOODIT
Kirjallisuusviite
Kuva
Linkki toiselle sivustolle
Lisätietoa
Näytönastekatsaus
PDF-tiedosto
PubMed-abstrakti
Taulukko